Logo image of CDXS

CODEXIS INC (CDXS) Stock Price, Quote, News and Overview

NASDAQ:CDXS - Nasdaq - US1920051067 - Common Stock - Currency: USD

2.33  -0.22 (-8.63%)

After market: 2.54 +0.21 (+9.01%)

CDXS Quote, Performance and Key Statistics

CODEXIS INC

NASDAQ:CDXS (5/28/2025, 8:00:02 PM)

After market: 2.54 +0.21 (+9.01%)

2.33

-0.22 (-8.63%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High6.08
52 Week Low1.9
Market Cap193.02M
Shares82.84M
Float80.82M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO04-22 2010-04-22


CDXS short term performance overview.The bars show the price performance of CDXS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

CDXS long term performance overview.The bars show the price performance of CDXS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of CDXS is 2.33 USD. In the past year, price decreased by -31.07%.

CODEXIS INC / CDXS Daily stock chart

CDXS Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 18.36 151.80B
DHR DANAHER CORP 25.37 135.27B
A AGILENT TECHNOLOGIES INC 20.88 31.61B
MTD METTLER-TOLEDO INTERNATIONAL 28.61 24.05B
IQV IQVIA HOLDINGS INC 12.28 24.01B
WAT WATERS CORP 29.77 21.10B
WST WEST PHARMACEUTICAL SERVICES 31.84 15.19B
ILMN ILLUMINA INC 25.35 13.37B
RVTY REVVITY INC 18.53 10.77B
ICLR ICON PLC 9.54 10.40B
QGEN QIAGEN N.V. 19.3 9.61B
TEM TEMPUS AI INC N/A 9.21B

About CDXS

Company Profile

CDXS logo image Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. The company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. The company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Company Info

CODEXIS INC

200 Penobscot Dr

Redwood City CALIFORNIA 94063 US

CEO: John J. Nicols

Employees: 188

CDXS Company Website

CDXS Investor Relations

Phone: 16504218100

CODEXIS INC / CDXS FAQ

What is the stock price of CODEXIS INC today?

The current stock price of CDXS is 2.33 USD. The price decreased by -8.63% in the last trading session.


What is the ticker symbol for CODEXIS INC stock?

The exchange symbol of CODEXIS INC is CDXS and it is listed on the Nasdaq exchange.


On which exchange is CDXS stock listed?

CDXS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CODEXIS INC stock?

13 analysts have analysed CDXS and the average price target is 7.48 USD. This implies a price increase of 221.03% is expected in the next year compared to the current price of 2.33. Check the CODEXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CODEXIS INC worth?

CODEXIS INC (CDXS) has a market capitalization of 193.02M USD. This makes CDXS a Micro Cap stock.


How many employees does CODEXIS INC have?

CODEXIS INC (CDXS) currently has 188 employees.


What are the support and resistance levels for CODEXIS INC (CDXS) stock?

CODEXIS INC (CDXS) has a support level at 2.32 and a resistance level at 2.43. Check the full technical report for a detailed analysis of CDXS support and resistance levels.


Is CODEXIS INC (CDXS) expected to grow?

The Revenue of CODEXIS INC (CDXS) is expected to decline by -8.74% in the next year. Check the estimates tab for more information on the CDXS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CODEXIS INC (CDXS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CODEXIS INC (CDXS) stock pay dividends?

CDXS does not pay a dividend.


When does CODEXIS INC (CDXS) report earnings?

CODEXIS INC (CDXS) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of CODEXIS INC (CDXS)?

CODEXIS INC (CDXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).


What is the Short Interest ratio of CODEXIS INC (CDXS) stock?

The outstanding short interest for CODEXIS INC (CDXS) is 7.04% of its float. Check the ownership tab for more information on the CDXS short interest.


CDXS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CDXS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CDXS. CDXS may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDXS Financial Highlights

Over the last trailing twelve months CDXS reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS decreased by -6.45% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.77%
ROE -150.03%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%-56.25%
Sales Q2Q%-55.82%
EPS 1Y (TTM)-6.45%
Revenue 1Y (TTM)-32.89%

CDXS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CDXS. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 19.37% and a revenue growth -8.74% for CDXS


Ownership
Inst Owners81.43%
Ins Owners2.41%
Short Float %7.04%
Short Ratio6.17
Analysts
Analysts81.54
Price Target7.48 (221.03%)
EPS Next Y19.37%
Revenue Next Year-8.74%